MA40768B1 - Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue - Google Patents

Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue

Info

Publication number
MA40768B1
MA40768B1 MA40768A MA40768A MA40768B1 MA 40768 B1 MA40768 B1 MA 40768B1 MA 40768 A MA40768 A MA 40768A MA 40768 A MA40768 A MA 40768A MA 40768 B1 MA40768 B1 MA 40768B1
Authority
MA
Morocco
Prior art keywords
dengue virus
mono
indole derivatives
substituted indole
virus replication
Prior art date
Application number
MA40768A
Other languages
English (en)
Other versions
MA40768A (fr
Inventor
Tim Jonckers
Pierre Raboisson
Bart Kesteleyn
Jean-François Bonfanti
Dorothée Bardiot
Arnaud Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40768(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of MA40768A publication Critical patent/MA40768A/fr
Publication of MA40768B1 publication Critical patent/MA40768B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des dérivés indole mono ou di-substitués (i) qui sont utiles pour prévenir ou traiter les infections par le virus de la dengue et concerne également lesdits composés destinés à être utilisés en tant que médicament, plus préférentiellement destinés à être utilisés en tant que médicament pour traiter ou prévenir les infections provoquées par le virus de la dengue. La présente invention concerne en outre des compositions pharmaceutiques ou des préparations combinées des composés, des compositions ou des préparations qui sont utilisées en tant que médicament, plus préférentiellement dans la prévention ou le traitement des infections provoquées par le virus de la dengue. L'invention concerne également des procédés de préparation des composés.
MA40768A 2014-10-01 2015-09-30 Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue MA40768B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14187374 2014-10-01
EP15159164 2015-03-16
PCT/EP2015/072551 WO2016050841A1 (fr) 2014-10-01 2015-09-30 Dérivés indole mono ou di-substitués en tant qu'inhibiteurs de la réplication du virus de la dengue
EP15771136.7A EP3201176B1 (fr) 2014-10-01 2015-09-30 Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue

Publications (2)

Publication Number Publication Date
MA40768A MA40768A (fr) 2017-09-08
MA40768B1 true MA40768B1 (fr) 2019-03-29

Family

ID=54199687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40768A MA40768B1 (fr) 2014-10-01 2015-09-30 Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue

Country Status (31)

Country Link
US (1) US9944598B2 (fr)
EP (1) EP3201176B1 (fr)
JP (1) JP6732736B2 (fr)
KR (1) KR102478311B1 (fr)
CN (1) CN107001264B (fr)
AU (1) AU2015326930B2 (fr)
BR (1) BR112017006299A2 (fr)
CA (1) CA2959573A1 (fr)
CL (1) CL2017000782A1 (fr)
CY (1) CY1121874T1 (fr)
DK (1) DK3201176T3 (fr)
EA (1) EA032546B1 (fr)
ES (1) ES2714074T3 (fr)
HR (1) HRP20190199T1 (fr)
HU (1) HUE041888T2 (fr)
IL (1) IL251396A0 (fr)
LT (1) LT3201176T (fr)
MA (1) MA40768B1 (fr)
ME (1) ME03360B (fr)
MX (1) MX2017004299A (fr)
PH (1) PH12017500571A1 (fr)
PL (1) PL3201176T3 (fr)
PT (1) PT3201176T (fr)
RS (1) RS58461B1 (fr)
SG (1) SG11201702463YA (fr)
SI (1) SI3201176T1 (fr)
TW (1) TWI681951B (fr)
UA (1) UA121119C2 (fr)
UY (1) UY36340A (fr)
WO (1) WO2016050841A1 (fr)
ZA (1) ZA201702301B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
ME03344B (fr) * 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Indoles monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR102457840B1 (ko) 2014-10-01 2022-10-21 메르크 파텐트 게엠베하 보론산 유도체
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
WO2017167953A1 (fr) * 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018068956A2 (pt) * 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) * 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors

Also Published As

Publication number Publication date
EP3201176B1 (fr) 2018-12-12
CN107001264A (zh) 2017-08-01
UY36340A (es) 2016-04-01
DK3201176T3 (en) 2019-03-25
SI3201176T1 (sl) 2019-05-31
MA40768A (fr) 2017-09-08
UA121119C2 (uk) 2020-04-10
CY1121874T1 (el) 2020-10-14
ES2714074T3 (es) 2019-05-27
SG11201702463YA (en) 2017-04-27
IL251396A0 (en) 2017-05-29
EP3201176A1 (fr) 2017-08-09
TWI681951B (zh) 2020-01-11
EA201790758A1 (ru) 2017-07-31
AU2015326930B2 (en) 2020-03-26
ME03360B (fr) 2019-10-20
PT3201176T (pt) 2019-03-04
US9944598B2 (en) 2018-04-17
HUE041888T2 (hu) 2019-06-28
AU2015326930A1 (en) 2017-03-16
US20170298017A1 (en) 2017-10-19
EA032546B1 (ru) 2019-06-28
BR112017006299A2 (pt) 2018-01-16
KR102478311B1 (ko) 2022-12-15
ZA201702301B (en) 2018-12-19
JP2017531619A (ja) 2017-10-26
PH12017500571A1 (en) 2017-08-30
RS58461B1 (sr) 2019-04-30
LT3201176T (lt) 2019-03-25
WO2016050841A1 (fr) 2016-04-07
CA2959573A1 (fr) 2016-04-07
HRP20190199T1 (hr) 2019-04-05
TW201630879A (zh) 2016-09-01
MX2017004299A (es) 2017-07-19
KR20170063802A (ko) 2017-06-08
CN107001264B (zh) 2021-06-15
WO2016050841A9 (fr) 2016-06-02
CL2017000782A1 (es) 2017-11-03
JP6732736B2 (ja) 2020-07-29
PL3201176T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MX2017009309A (es) Derivados de indol mono o disustituido como inhibidores de la replicacion del virus del dengue.
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA43507B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses